Table 1.
Baseline Clinical Characteristics of the Study Cohort
| Patient characteristics | % (n) |
|---|---|
| RET germline mutationa | 13% (3) |
| Preoperative calcitonina (pg/mL) | |
| Median ± standard deviation | 1403 ± 20,491 |
| Range | 12–98,562 |
| Preoperative CEAb (ng/mL) | |
| Median ± standard deviation | 45.5 ± 148.1 |
| Range | 4–621 |
| Compressive symptoms at presentation | 13% (4) |
| pN1b at presentation | 47% (14) |
| M1 at presentation | 13% (4) |
| Stage I–II | 40% (12) |
| Stage III | 10% (3) |
| Stage IV | 50% (15) |
Stages of MTC according to the sevent edition of the American Joint Committee on Cancer classification.
a
Information was available in 23 patients (77%).
b
Information available in 17 patients (57%).
CEA, carcinoembryonic antigen.